Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...

The US Food and Drug Administration (FDA) has approved an alternative formulation for Neurocrine Biosciences’ Huntington’s disease therapy, Ingrezza (valbenazine). The new formulation ...

Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...

Chief Commercial Officer Eric Benevich noted that INGREZZA achieved record annual ... clinicians to gain real-world experience with the drug. Management reiterated their confidence in CRENESSITY ...

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives. Neurocrine ...

INGREZZA Sales Guidance for 2025 ... A: Eric Benevich, Chief Commercial Officer, stated that they are pleased with the early approval and broad label for CRENESSITY. They will provide quarterly ...

Ingrezza fourth quarter and fiscal 2024 net product sales were $615 million and $2.3 billion, respectively. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan ...

Ingrezza fourth quarter and fiscal 2024 net product sales were $615 million and $2.3 billion, respectively. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires ...